Search

Your search keyword '"Rogerio Lilenbaum"' showing total 4 results
Start Over Author "Rogerio Lilenbaum" Publisher harborside press, llc
4 results on '"Rogerio Lilenbaum"'

1. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018

Author

Matthew A. Gubens, Theresa A. Shapiro, Douglas E. Wood, Gregory J. Riely, Lucian R. Chirieac, Karen L. Reckamp, Leora Horn, Renato G. Martins, Gregory A. Otterson, Michael C. Dobelbower, David S. Ettinger, Rudy P. Lackner, Kurt Tauer, Dara L. Aisner, Sandip Pravin Patel, Stephen C. Yang, Michael Lanuti, Kristina M. Gregory, James P. Stevenson, Scott J. Swanson, Ticiana A. Leal, Billy W. Loo, Jules Lin, Mark Hennon, Rogerio Lilenbaum, Miranda Hughes, Ramaswamy Govindan, Joe Y. Chang, Thomas A. D'Amico, Thomas J. Dilling, Steven E. Schild, Wallace Akerley, and Jessica Bauman

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Medical Oncology, Neoplasm genetics, Targeted therapy, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Medicine, Molecular Targeted Therapy, Progression-free survival, Lung cancer, Societies, Medical, Randomized Controlled Trials as Topic, business.industry, Disease progression, medicine.disease, Progression-Free Survival, United States, respiratory tract diseases, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Mutation, Disease Progression, Non small cell, business
Abstract

The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the targeted therapy and immunotherapy sections in the NCCN Guidelines. For the 2018 update, a new section on biomarkers was added.

Published
2018
Full Text
View/download PDF

2. Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Author

Lucian R. Chirieac, Jessica Bauman, Thomas A. D'Amico, Thomas J. Dilling, Leah J. Leisch, Steven E. Schild, Ticiana A. Leal, Douglas E. Wood, Scott J. Swanson, Robert C. Doebele, Wallace Akerley, Renato Martins, James P. Stevenson, Mark Hennon, Leora Horn, Rogerio Lilenbaum, Malcolm M. DeCamp, Gregory A. Otterson, Dara L. Aisner, Kristina M. Gregory, Miranda Hughes, Karen L. Reckamp, Ramaswamy Govindan, Theresa A. Shapiro, Billy W. Loo, Matthew A. Gubens, Jules Lin, Gregory J. Riely, David S. Ettinger, Rudy P. Lackner, Kurt Tauer, Michael Lanuti, Ritsuko Komaki, Michael C. Dobelbower, and Stephen C. Yang

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Disease, Pembrolizumab, 03 medical and health sciences, 0302 clinical medicine, Recurrence, Atezolizumab, Carcinoma, Non-Small-Cell Lung, Internal medicine, Humans, Medicine, Combined Modality Therapy, Osimertinib, Molecular Targeted Therapy, Neoplasm Metastasis, Lung cancer, Clinical Trials as Topic, Ceritinib, business.industry, Disease Management, Immunotherapy, Prognosis, medicine.disease, respiratory tract diseases, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, business, Biomarkers, medicine.drug
Abstract

This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.

Published
2017
Full Text
View/download PDF

3. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016

Author

Lyudmila Bazhenova, Thierry Jahan, Jyoti D. Patel, Scott J. Swanson, Ramaswamy Govindan, Jules Lin, Gregory A. Otterson, Kurt Tauer, Karen L. Reckamp, M. Chris Dobelbower, Thomas A. D'Amico, Lucian R. Chirieac, Wallace Akerley, Thomas J. Dilling, D.R. Camidge, Katherine M.W. Pisters, Stephen C. Yang, Michael Lanuti, James P. Stevenson, Neelesh Sharma, Mark Hennon, Rogerio Lilenbaum, Renato G. Martins, Miranda Hughes, Gregory J. Riely, David S. Ettinger, Leora Horn, Rudy P. Lackner, Steven E. Schild, Billy W. Loo, Richard T. Cheney, Theresa A. Shapiro, Kristina M. Gregory, Douglas E. Wood, Ritsuko Komaki, and Hossein Borghaei

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, Pembrolizumab, medicine.disease, Surgery, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Docetaxel, 030220 oncology & carcinogenesis, Internal medicine, medicine, In patient, Non small cell, Nivolumab, Lung cancer, Adverse effect, business, Survival rate, medicine.drug
Abstract

These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

Published
2016
Full Text
View/download PDF

4. Non–Small Cell Lung Cancer, Version 1.2015

Author

Kristina M. Gregory, Gregory A. Otterson, Ramaswamy Govindan, Rogerio Lilenbaum, Miranda Hughes, Jules Lin, Scott J. Swanson, Steven E. Schild, Douglas E. Wood, Ritsuko Komaki, Renato G. Martins, Leora Horn, Katherine M.W. Pisters, Lucian R. Chirieac, Rudy P. Lackner, Frederic W. Grannis, Todd L. Demmy, Karen L. Reckamp, Kurt Tauer, Theresa A. Shapiro, Thomas A. D'Amico, Lee M. Krug, Thomas J. Dilling, Billy W. Loo, Eric M. Rohren, Michael Lanuti, David S. Ettinger, D.R. Camidge, Wallace Akerley, Hossein Borghaei, Lyudmila Bazhenova, Richard T. Cheney, Thierry Jahan, Stephen C. Yang, Gregory J. Riely, Mark G. Kris, and Jyoti D. Patel

Subjects
Oncology, medicine.medical_specialty, Lung Neoplasms, Palliative care, business.industry, medicine.medical_treatment, Palliative Care, Guidelines as Topic, medicine.disease, Combined Modality Therapy, Radiation therapy, Clinical Practice, Carcinoma, Non-Small-Cell Lung, Internal medicine, medicine, Carcinoma, Humans, Non small cell, Medical prescription, Lung cancer, business
Abstract

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) focuses on the principles of radiation therapy (RT), which include the following: (1) general principles for early-stage, locally advanced, and advanced/metastatic NSCLC; (2) target volumes, prescription doses, and normal tissue dose constraints for early-stage, locally advanced, and advanced/palliative RT; and (3) RT simulation, planning, and delivery. Treatment recommendations should be made by a multidisciplinary team, including board-certified radiation oncologists who perform lung cancer RT as a prominent part of their practice.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results